Interactive Agenda Click on the ABSTRACT button to see details for each item
TUESDAY SEPTEMBER 14 |
|
8:30a - 6:00p |
REGISTRATION |
| 1:30p - 5:00p | PEPTIDE SHOWCASE This session features short presentations from companies involved in the development of peptide therapeutics or peptide related technologies.  |
5:30p - 6:30p |
OPENING NIGHT RECEPTION |
WEDNESDAY SEPTEMBER 15 |
|
7:30a - 8:30a |
BREAKFAST |
| 8:30a – 11:25a | SESSION IA – PEPTIDES IN THE CLINIC
Shk Peptides For The Treatment Of Autoimmune Disease Shawn Iadonato, Chief Scientific Officer Kineta Bio Oral Delivery of Peptides using GIPET® Technology Tom Leonard,Vice President & Chief Scientific Officer Merrion PharmaceuticalsApolipoprotein E Peptide Mimetics
Dennis I. Goldberg, President and CEO Lipimetix LLCGuanylate Cyclase-C Agonists as a New Class of Drug Candidates for GI disorders and Inflammatory Bowel Disease Kunwar Shailubhai, Chief Scientific Officer Synergy Pharmaceuticals |
11:25a – 12:25p |
KEYNOTE ADDRESS
Stephen BH Kent - Peptides for Pleasure and for Profit |
12:25p – 1:25p |
LUNCH |
1:25p – 4:30p |
SESSION II – DRUG DELIVERY AND FORMULATION
The Role Of Peptide Properties During Microencapsulation And Extended-Release From Bioresorbable Polymers
Tom Tice, Vice-President Research Surmodics IncAre today's medicinal chemists better prepared to design therapeutic peptides that exhibit good oral bioavailability?
Ronald T. Borchardt
, Solon E. Summerfield Distinguished Professor The University Of Kansas
TPE, A Unique Formulation Based Technology Enabling Oral Delivery Of Macromolecules
Roni Mamluk
, Chief Operating Officer ChiasmaPEGylation: a successful strategy in parenteral drug delivery
Francesco M. Veronese
, Professor, Applied Pharmaceutical Chemistry Padua University |
6:00p – 7:00p |
MEIENHOFER AWARD PRESENTATION |
7:00p – 9:00p |
GALA DINNER AT THE RED LION INN |
THURSDAY SEPTEMBER 16 |
|
7:00a – 8:00a |
BREAKFAST |
8:00a – 12:20p |
SESSION IB – PEPTIDES IN THE CLINIC
Development Of A Nonapeptide (Syn1002) For The Treatment Of Autoimmune Diseases And Neuropathic Pain Jamal Temsamani, Vice-President R&D CLL PharmaTherapeutic Applications Of Synthetic HDL Mimetic Proteins Composed Of alpha-Helical Peptide Strands Jan Johannson, CEO and John Bielicki, Founder Artery TherapeuticsSESSION III – CELL PENETRATING PEPTIDES AND TISSUE TARGETING
Pepducins: Novel Lipopeptide Allosteric Modulators Of Gpcr Signaling
Steve Hunt, Chief Scientific Officer Anchor TherapeuticsTargeted Delivery of Bioactive Cell Penetrating Peptides: Implications for Anti-cancer Therapy
John Howl, Professor of Molecular Pharmacology University of WolverhamptonEnsemblins: A New Class Of Therapeutic Macrocycles
Nicholas Terrett, Chief Scientific Officer Ensemble Discovery Corp.Cyclotides, a novel natural peptide scaffold for drug discovery
Julio Camarero, Associate Professor fo Pharmacology Univ. of Southern California |
12:20p – 1:20p |
LUNCH |
1:20p – 3:20p |
SESSION IV – ADVANCES IN PEPTIDE CHEMISTRY AND ANALYTICS
Peptides On Synthetic Scaffolds For Mimicry Of Proteins Towards Synthetic Vaccines And Beyond
Rob M.J. Liskamp
, Professor Utrecht University
Analytical Challenges On Pegylated Peptide API
Ping Zhuang
, Research Fellow Merck and Co.Umpolung Amide Synthesis
Jeffrey Johnston
, Professor of Chemistry Vanderbilt University & Institute Of Chemical Biology Discovery Of Potent, Cyclic Calcitonin Gene Related Peptide (CGRP) Receptor Antagonists
John P. Mayer
, Senior Research Advisor and Group Leader Eli Lilly and Co.Synthesis of Insulin Like Peptides by Random Folding of A and B Chains Founder
, Professor University of Patras |
3:20p – 5:30p |
POSTER SESSION |
6:00p – 8:00p |
NETWORKING RECEPTION |